2. Search Result
Search Result
Results for "

microglia activation

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

1

Biochemical Assay Reagents

6

Peptides

1

Inhibitory Antibodies

8

Natural
Products

2

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-121035
    7BIO

    7-Bromoindirubin-3-Oxime

    		 CDK GSK-3 Neurological Disease
    7BIO (7-Bromoindirubin-3-Oxime) is the derivate of indirubin. 7BIO (7-Bromoindirubin-3-Oxime) has inhibitory effects against cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3β (GSK3β). 7BIO (7-Bromoindirubin-3-Oxime) inhibits Aβ oligomer-induced neuroinflammation, synaptic impairments, tau hyper-phosphorylation, activation of astrocytes and microglia, and attenuates Aβ oligomer-induced cognitive impairments in mice [1].
    7BIO
  • HY-B1197
    Amcinonide

    CL-34699

    		 Glucocorticoid Receptor Inflammation/Immunology Endocrinology
    Amcinonide is a NO inhibitor that inhibits NO release from activated microglia with IC50 of 3.38 nM. Amcinonide has glucocorticoid receptor affinity .
    Amcinonide
  • HY-146086
    Nrf2 activator-4

    		Keap1-Nrf2 Reactive Oxygen Species Neurological Disease Inflammation/Immunology
    Nrf2 activator-4 (Compound 20a) is a highly potent, orally active Nrf2 activator with an EC50 of 0.63 µM. Nrf2 activator-4 suppresses reactive oxygen species against oxidative stress in microglia. Nrf2 activator-4 effectively recovers the learning and memory impairment in a scopolamine-induced mouse model .
    Nrf2 activator-4
  • HY-101860
    GIBH-130
    3 Publications Verification

    		 Interleukin Related Neurological Disease
    GIBH-130 is an effective inhibitor of neuroinflammation. GIBH-130 significantly suppresses the IL-1β secretion by activated microglia (IC50=3.4 nM).
    GIBH-130
  • HY-162607
    STAT3-IN-28

    		STAT Inflammation/Immunology
    STAT3-IN-28 (compound 18) is a STAT3 inhibitor. STAT3-IN-28 can inhibit the activation of microglia and has anti-neuroinflammatory effects. STAT3-IN-28 can cross the blood-brain barrier .
    STAT3-IN-28
  • HY-N10458
    Asperbisabolane L

    		NF-κB Inflammation/Immunology
    Asperbisabolane L, a sesquiterpenoid, exerts the anti-inflammatory activity by inhibiting the NF-κB-activated pathway. Asperbisabolane L inhibits the translocation of NF-κB from cytoplasm to the nucleus. Asperbisabolane L also inhibits NO production in LPS-activated BV-2 microglia cells .
    Asperbisabolane L
  • HY-N10782
    Balanophonin

    		Apoptosis COX TNF Receptor p38 MAPK Neurological Disease Inflammation/Immunology Cancer
    Balanophonin is an anti-inflammatory and anti-cancer agent. Balanophonin inhibits microglial activation and neurodegeneration via inhibiting activated microglia-induced apoptosis .
    Balanophonin
  • HY-N7018
    20-Hydroxyganoderic Acid G

    		Others Inflammation/Immunology
    20-Hydroxyganoderic Acid G is a lanostane triterpenoid obtained from the EtOH extract of fruiting bodies of the Ganoderma curtisii. 20-Hydroxyganoderic Acid G inhibits BV-2 microglia cells activated by LPS with an IC50 of 21.33 μM. 20-Hydroxyganoderic Acid G has therapeutic potential in the agent discovery of nerve inflammation diseases associated with microglia activated by LPS .
    20-Hydroxyganoderic Acid G
  • HY-N0859B
    Schisanchinin D

    		NO Synthase Neurological Disease
    Schisanchinin D is an NO release inhibitor found in the fruits of Schisandra chinensis. Schisanchinin D can inhibit the release of nitric oxide (NO) by lipopolysaccharide (LPS)-activated microglia in primary murine BV2 microglia cells. Schisanchinin D is promising for research of neurodegenerative diseases such as Alzheimer's disease (AD) .
    Schisanchinin D
  • HY-N6261
    Epimagnolin B

    		Others Inflammation/Immunology
    Epimagnolin B is a bisepoxylignan isolated from Magnolia fargesii, with anti-inflammatory activity and antiallergic effects. Epimagnolin B inhibits NO production in LPS-activated microglia. Epimagnolin B exhibited antiallergic effects .
    Epimagnolin B
  • HY-B0763S1
    Ibudilast-d7

    		Isotope-Labeled Compounds Phosphodiesterase (PDE) Inflammation/Immunology Cancer
    Ibudilast-d7 is the deuterium labeled Ibudilast. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia[1].
    Ibudilast-d7
  • HY-123506
    Fenlean

    		Src Neurological Disease Inflammation/Immunology
    Fenlean, a natural squamosamide derivative, is a Src tyrosine kinase inhibitor. Fenlean can inhibit over-activated microglia and protect dopaminergic neurons. Fenlean can attenuate neuroinflammation in Parkinson's disease models .
    Fenlean
  • HY-157430
    BET-IN-21

    		Epigenetic Reader Domain Neurological Disease
    BET-IN-21 (compound 16) is a blood-brain barrier-permeable extra terminal domain (BET) inhibitor with the Ki of 230 nM. BET-IN-21 inhibits microglia activation and has ameliorative effects on experimental autoimmune encephalomyelitis mice .
    BET-IN-21
  • HY-W041892
    Dimethyl itaconate

    		Reactive Oxygen Species Infection Neurological Disease Inflammation/Immunology
    Dimethyl itaconate induces innate immune memory (trained immunity), and exhibits immunomodulatory property. Dimethyl itaconate inhibits the activation of microglia, reduces the neuroinflammation and synaptic structural damage. Dimethyl itaconate regulates the composition of intestinal flora .
    Dimethyl itaconate
  • HY-B0763S2
    Ibudilast-d7-1

    KC-404-d7-1; AV-411-d7-1; MN-166-d7-1

    		 Phosphodiesterase (PDE) Inflammation/Immunology
    Ibudilast-d7-1 is the deuterium labeled Ibudilast[1]. Ibudilast (KC-404;AV-411;MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia[2].
    Ibudilast-d7-1
  • HY-P5762
    Phoenixin-14

    PNX-14

    		 GnRH Receptor Neurological Disease
    Phoenixin-14 (PNX-14) is one of the endogenous active isoform, and generates anxiolytic effect via the activation of the AHA GnRH system in mice. Phoenixin-14 inhibits ischemia/reperfusion-induced cytotoxicity in microglia .
    Phoenixin-14
  • HY-N0131
    Stigmasterol
    Maximum Cited Publications
    7 Publications Verification

    		 MMP Endogenous Metabolite Neurological Disease Inflammation/Immunology
    Stigmasterol is an orally acitve, immunomodulatory agent with anti-inflammatory and neuroprotective effect, as well as able to cross the blood-brain barrier. Stigmasterol activates AMPK, which in turn inhibits NF-κB and NLRP3 signaling pathways, reduces microglia-mediated neuroinflammation, and alleviates cognitive impairment and Alzheimer's disease. Stigmasterol regulates M1/M2 polarization of microglia through the TLR4/ NF-κB pathway, thereby reducing neuropathic pain. Stigmasterol can be used for neurodegenerative diseases, inflammatory diseases, and pain management, among others .
    Stigmasterol
  • HY-107541
    O-1602
    2 Publications Verification

    		 GPR55 Neurological Disease
    O-1602 is an agonist of GPR55 (G protein-coupled receptor 55). O-1602 reduces the number and activation of hippocampal microglia induced by METH (methamphetamine). O-1602 decreases the expression levels of NLRP3 inflammasome proteins, including NLRP3, ASC and Caspase-1 .
    O-1602
  • HY-P1241A
    BAM(8-22) TFA

    		Mas-related G-protein-coupled Receptor (MRGPR) Neurological Disease Inflammation/Immunology
    BAM(8-22) TFA, a proteolytically cleaved product of proenkephalin A and sensory neuron-specific receptor (SNSR) agonist, is a potent activator of Mas-related G-protein-coupled receptors (Mrgprs), MrgprC11 and hMrgprX1. BAM(8-22) TFA induces scratching in mice in an Mrgpr-dependent manner. In addition, BAM(8-22) TFA has an analgesic effect and can also inhibit the activation of microglia .
    BAM(8-22) TFA
  • HY-P1241
    BAM(8-22)

    		Mas-related G-protein-coupled Receptor (MRGPR) Neurological Disease Inflammation/Immunology
    BAM(8-22), a proteolytically cleaved product of proenkephalin A and sensory neuron-specific receptor (SNSR) agonist, is a potent activator of Mas-related G-protein-coupled receptors (Mrgprs), MrgprC11 and hMrgprX1. BAM(8-22) induces scratching in mice in an Mrgpr-dependent manner. In addition, BAM(8-22) has an analgesic effect and can also inhibit the activation of microglia .
    BAM(8-22)
  • HY-B0763
    Ibudilast
    5+ Cited Publications

    KC-404; AV-411; MN-166

    		 Phosphodiesterase (PDE) Inflammation/Immunology Cancer
    Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .
    Ibudilast
  • HY-146765
    AMS-17

    		NOD-like Receptor (NLR) Neurological Disease Inflammation/Immunology
    AMS-17 is a potent NLRP3 inhibitor, inhibiting microglia activation in vitro and in vivo. AMS-17 also inhibits cytokines such as caspase-1, TNF-α, IL-1β and inducible nitric oxide synthase (iNOS) in N9 cells. AMS-17 can be used for researching inflammation-associated neurological disorders .
    AMS-17
  • HY-P990043
    Iluzanebart

    		Ser/Thr Kinase TREM receptor Inflammation/Immunology
    Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .
    Iluzanebart
  • HY-B0763R
    Ibudilast (Standard)

    		Phosphodiesterase (PDE) Inflammation/Immunology Cancer
    Ibudilast (Standard) is the analytical standard of Ibudilast. This product is intended for research and analytical applications. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .
    Ibudilast (Standard)
  • HY-107541R
    O-1602 (Standard)

    		GPR55 Neurological Disease
    O-1602 (Standard) is the analytical standard of O-1602. This product is intended for research and analytical applications. O-1602 is an agonist of GPR55 (G protein-coupled receptor 55). O-1602 reduces the number and activation of hippocampal microglia induced by METH (methamphetamine). O-1602 decreases the expression levels of NLRP3 inflammasome proteins, including NLRP3, ASC and Caspase-1 .
    O-1602 (Standard)
  • HY-P10824
    RI-OR2-TAT

    		Amyloid-β Neurological Disease
    RI-OR2-TAT is a brain-penetrant inhibitor of β-Amyloid oligomerization, which is produced by adding the HIV protein transduction domain TAT to RI-OR2. RI-OR2-TAT binds to Aβ42 fibrils with a Kd value of 58-125 nM. RI-OR2-TAT reduces Aβ aggregation and plaque levels, reduces activation of microglia and oxidative damage, and increases the number of young neurons in the dentate gyrus .
    RI-OR2-TAT
  • HY-173334
    hMAO-B-IN-11

    		Monoamine Oxidase Interleukin Related TNF Receptor Neurological Disease
    hMAO-B-IN-11 (Compound 12) is a selective and reversible inhibitor of human monoamine oxidase B (hMAO-B) with an IC50 of 0.11 µM. hMAO-B-IN-11 acts through competitive binding to the hMAO-B active site, preventing oxidative deamination of monoamines and reducing hydrogen peroxide production. hMAO-B-IN-11 also inhibits pro-inflammatory mediators (NO, TNF-α, IL-1β) in activated microglia, hMAO-B-IN-11 is promising for research of neurodegenerative diseases like Parkinson’s and Alzheimer’s .
    hMAO-B-IN-11
  • HY-171031
    TFGF-18

    		GSK-3 Apoptosis Caspase Bcl-2 Family Reactive Oxygen Species Neurological Disease
    TFGF-18 is a GSK-3β inhibitor (IC50: 0.59 μM). TFGF-18 inhibits LPS-induced microglia activation and proinflammatory mediators release via inhibiting GSK-3β and downstream p65/NF-κB signaling. TFGF-18 inhibits neuronal apoptosis and oxidative stress, inhibits expressions of Bax, caspase3 and cleaved-caspase3 and increases the expression of Bcl-2. TFGF-18 has neuroprotection effect, inhibit neuroinflammation and attenuates cognitive impairment .
    TFGF-18
  • HY-113509B
    15(R)-Lipoxin A4

    15-epi-LXA4

    		 STAT Neurological Disease Inflammation/Immunology
    15(R)-Lipoxin A4 (15-epi-LXA4) is a STAT-6 activator and a lipid-derived lipoxin-type specialized pro-resolving mediator (SPM) that plays a role in promoting inflammation resolution and regulating immune cell function. 15(R)-Lipoxin A4 can improve the phagocytic function of microglia and exhibits anti-inflammatory activity. In Alzheimer's disease (AD) mouse models, 15(R)-Lipoxin A4 improves AD-like pathology. 15(R)-Lipoxin A4 holds potential for use in inflammation and neurodegenerative disease research .
    15(R)-Lipoxin A4
  • HY-N2909
    Aurantiamide

    		NF-κB RIP kinase Mixed Lineage Kinase Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as RIPK3/MLKL signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models .
    Aurantiamide